More articles from Editorial

  • Immunoglobulin E: From horses to myeloma

    Adam J. Brown, MD
    • Cleveland Clinic Journal of Medicine October 2026, 93 (10) 589-591;
    • DOI: https://doi.org/10.3949/ccjm.93a.26078
    • The author explores how IgE was discovered, the challenges researchers faced when isolating the antibody, and the connection among IgE, mast cells, and histamine.

  • New guidance on primary aldosteronism: Rethinking screening in hypertension

    George Thomas, MD
    • Cleveland Clinic Journal of Medicine September 2026, 93 (9) 525-526;
    • DOI: https://doi.org/10.3949/ccjm.93a.26073
    • The 2025 Endocrine Society guideline is best viewed not as the final word on primary aldosteronism, but as the beginning of an important conversation.

  • An emergency physician’s opinion on kratom confusion

    John R. Queen, MD
    • Cleveland Clinic Journal of Medicine August 2026, 93 (8) 493-495;
    • DOI: https://doi.org/10.3949/ccjm.93a.26031
    • There is much confusion about who is using kratom, what the drug does, and what we physicians should do about it.

  • Pulmonary nodule management—patients first, guidelines second

    Louis S. H. Lam, MD
    • Cleveland Clinic Journal of Medicine August 2026, 93 (8) 485-486;
    • DOI: https://doi.org/10.3949/ccjm.93a.26060
    • How we communicate nodule findings to our patients can influence their perception and whether they agree with and adhere to recommendations.

  • KDIGO chronic kidney disease heat map: Let the colors be your guide!

    Crystal Gadegbeku, MD
    • Cleveland Clinic Journal of Medicine June 2026, 93 (6) 366-367;
    • DOI: https://doi.org/10.3949/ccjm.93a.26017
    • Clinicians need to adopt early interventions that can alter the course of chronic kidney disease for patients.

  • Treating perinatal mood and anxiety disorders: A call to action

    Lulu Zhao, MD
    • Cleveland Clinic Journal of Medicine April 2026, 93 (4) 207-209;
    • DOI: https://doi.org/10.3949/ccjm.93a.26002
    • Perinatal mood and anxiety disorders remain untreated in 3 of 4 affected individuals giving birth.

  • Clinical application of the complement system: A historical perspective

    Adam J. Brown, MD
    • Cleveland Clinic Journal of Medicine April 2026, 93 (4) 237-239;
    • DOI: https://doi.org/10.3949/ccjm.93a.26014
    • Now that our understanding of complement has evolved to therapeutic targeting of components of the cascade in a wide range of diseases, it is time to give the complement system another look.

  • Xanthomas: A clue to undiagnosed lipid disorders

    Ashish Sarraju, MD
    • Cleveland Clinic Journal of Medicine February 2026, 93 (2) 76-77;
    • DOI: https://doi.org/10.3949/ccjm.93a.25116
    • Given the wide availability of direct-to-consumer laboratory testing, it is reasonable to ask whether a working knowledge of xanthomas still matters for trainees and clinicians.

  • LADA: A case for starting insulin therapy at diagnosis

    Byron J. Hoogwerf, MD
    • Cleveland Clinic Journal of Medicine December 2025, 92 (12) 764-766;
    • DOI: https://doi.org/10.3949/ccjm.92a.25084
    • The author discusses factors that support starting insulin therapy at diagnosis in all patients with latent autoimmune diabetes in adults.

  • Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction

    Nandan Kodur, BS and W. H. Wilson Tang, MD
    • Cleveland Clinic Journal of Medicine November 2025, 92 (11) 673-675;
    • DOI: https://doi.org/10.3949/ccjm.92a.25078
    • The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.

Previous